ATE470150T1 - Methode zum schnellen identifizieren von kleinen organischen liganden - Google Patents

Methode zum schnellen identifizieren von kleinen organischen liganden

Info

Publication number
ATE470150T1
ATE470150T1 AT99931882T AT99931882T ATE470150T1 AT E470150 T1 ATE470150 T1 AT E470150T1 AT 99931882 T AT99931882 T AT 99931882T AT 99931882 T AT99931882 T AT 99931882T AT E470150 T1 ATE470150 T1 AT E470150T1
Authority
AT
Austria
Prior art keywords
small organic
biological target
ligands
binding
organic molecule
Prior art date
Application number
AT99931882T
Other languages
English (en)
Inventor
Jim Wells
Dan Erlanson
Andrew Braisted
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE470150T1 publication Critical patent/ATE470150T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99931882T 1998-06-26 1999-06-25 Methode zum schnellen identifizieren von kleinen organischen liganden ATE470150T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/105,372 US6335155B1 (en) 1998-06-26 1998-06-26 Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
PCT/US1999/014267 WO2000000823A1 (en) 1998-06-26 1999-06-25 Methods for rapidly identifying small organic ligands

Publications (1)

Publication Number Publication Date
ATE470150T1 true ATE470150T1 (de) 2010-06-15

Family

ID=22305449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931882T ATE470150T1 (de) 1998-06-26 1999-06-25 Methode zum schnellen identifizieren von kleinen organischen liganden

Country Status (9)

Country Link
US (7) US6335155B1 (de)
EP (1) EP1090295B1 (de)
JP (1) JP2002519668A (de)
AT (1) ATE470150T1 (de)
AU (1) AU4829999A (de)
CA (1) CA2336183A1 (de)
DE (1) DE69942451D1 (de)
IL (2) IL140287A (de)
WO (1) WO2000000823A1 (de)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
US20050287596A9 (en) * 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US7214487B2 (en) * 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
CA2403296A1 (en) 2000-04-10 2001-10-18 Benjamin F. Cravatt Proteomic analysis using activity-based probe libraries
AU2001296645A1 (en) 2000-10-06 2002-04-15 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding dna and rna
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
US20050084908A1 (en) * 2000-11-06 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
CA2430234C (en) * 2000-11-21 2008-02-12 Sunesis Pharmaceuticals, Inc. An extended tethering approach for rapid identification of ligands
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
WO2002063271A2 (en) 2001-02-05 2002-08-15 Activx Biosciences, Inc. Activity based probe analysis
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10125258A1 (de) * 2001-05-23 2003-01-09 November Ag Molekulare Medizin Verfahren zur Bestimmung des Bindeverhaltens von an Ziel-Molekülen spezifisch bindenden Liganden
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
IL159983A0 (en) * 2001-08-07 2004-06-20 Sunesis Pharmaceuticals Inc Disulfide and thiosulfonate ligands and libraries comprising these ligands
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
GB0129012D0 (en) 2001-12-04 2002-01-23 Solexa Ltd Labelled nucleotides
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030186464A1 (en) * 2002-01-29 2003-10-02 Michelle Arkin Surface plasmon resonance methods
US20050084905A1 (en) * 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
WO2003087299A2 (en) * 2002-04-05 2003-10-23 Sunesis Pharmaceuticals, Inc. Methods of characterizing molecular interaction sites on proteins
CA2478395A1 (en) * 2002-04-08 2003-10-23 Sunesis Pharmaceuticals, Inc. Methods for identifying allosteric sites
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US8019550B2 (en) * 2002-07-24 2011-09-13 Keddem Bioscience Ltd. Drug discovery method
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
WO2004018497A2 (en) 2002-08-23 2004-03-04 Solexa Limited Modified nucleotides for polynucleotide sequencing
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
ATE354096T1 (de) 2002-12-23 2007-03-15 Astex Therapeutics Ltd Synthese und screening von liganden mit hilfe von röntgenkristallographie
US7019019B2 (en) * 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE602004027000D1 (de) * 2003-01-17 2010-06-17 Advanced Proteome Therapeutics Verfahren zur Identifizierung aktivierter Polymer-Komplexe zur sekundären Stellen-spezifischen Modifikation von Protein Ziel-Gruppen.
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP2784084B2 (de) 2003-07-08 2023-10-04 Novartis Pharma AG Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen
CA2543897A1 (en) 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
DK2295073T3 (da) 2003-11-17 2014-07-28 Genentech Inc Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
US7348416B2 (en) * 2003-11-21 2008-03-25 Applera Corporation Selective capture and enrichment of proteins expressed on the cell surface
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1922410A2 (de) 2005-08-15 2008-05-21 Genentech, Inc. Genunterbrechungen, zusammensetzungen und verfahren in verbindung damit
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
US7528365B2 (en) * 2006-02-07 2009-05-05 Applera Corporation Chemical noise reduction for mass spectrometry
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
JP2009536834A (ja) 2006-05-12 2009-10-22 ジェネンテック・インコーポレーテッド 癌の診断及び治療のための方法及び組成物
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US7879799B2 (en) * 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
EP2059529A2 (de) * 2006-08-22 2009-05-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Auswahlverfahren für gpcr-liganden
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
NZ577150A (en) 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
AU2008307145B2 (en) 2007-10-04 2014-07-10 Bionomics Limited Markers of endothelial cells and uses thereof
WO2009051807A1 (en) * 2007-10-19 2009-04-23 The Trustees Of Columbia University In The City Of New York Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis
KR101867606B1 (ko) 2007-11-07 2018-06-18 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
WO2009120795A1 (en) * 2008-03-25 2009-10-01 Sunesis Pharmaceuticals, Inc. Methods of chemotype evolution
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
EP3255060A1 (de) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zell-funktion
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
PH12012500982A1 (en) 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
CN102939110A (zh) 2010-04-21 2013-02-20 诺沃—诺迪斯克有限公司 蛋白质的选择性修饰
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
WO2012142526A1 (en) 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
US9624539B2 (en) 2011-05-23 2017-04-18 The Trustees Of Columbia University In The City Of New York DNA sequencing by synthesis using Raman and infrared spectroscopy detection
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP2015506944A (ja) 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
RU2014141617A (ru) 2012-03-16 2016-05-10 Дженентек, Инк. Сконструированные конформационно-стабилизированные белки
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
GB2517857A (en) 2012-04-25 2015-03-04 Biodesy Inc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
JP2016516046A (ja) 2013-03-14 2016-06-02 ジェネンテック， インコーポレイテッド がんの治療方法及びがん薬物耐性を阻止する方法
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014144883A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Raman cluster tagged molecules for biological imaging
WO2014139596A1 (en) 2013-03-15 2014-09-18 Illumina Cambridge Limited Modified nucleosides or nucleotides
CA2905123A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EP3808778A1 (de) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung der sichelzellenanämie
EP3636073B1 (de) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanisierte c5- und c3-tiere
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
EP2980125B1 (de) * 2014-07-28 2017-06-14 Wacker Chemie AG Verfahren zur Herstellung einer Aminosiloxan Polymer Nanoemulsion
EP2980126A1 (de) 2014-07-28 2016-02-03 Wacker Chemie AG Verfahren zur Herstellung einer Aminosiloxan Polymer Nanoemulsion
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
WO2016037157A2 (en) 2014-09-05 2016-03-10 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3273974A4 (de) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapie für maligne erkrankungen
MA41920B1 (fr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3311165B1 (de) 2015-06-19 2020-12-09 University Of Rochester Septinproteine als neuartige biomarker zur detektion und behandlung von müllerschen tumoren
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (de) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii-antagonist zur verwendung in der behandlung von augenerkrankungen
US11135221B2 (en) 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US11278550B2 (en) 2016-05-17 2022-03-22 Duke University Compositions and methods for the treatment of Prader-Willi syndrome
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
GB201614152D0 (en) 2016-08-18 2016-10-05 Imp Innovations Ltd Assay
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10202111663PA (en) 2017-02-27 2021-12-30 Regeneron Pharma Humanized model of kidney and liver disorders
CN110709702A (zh) 2017-03-24 2020-01-17 豪夫迈·罗氏有限公司 治疗自身免疫性疾病和炎性疾病的方法
EP3624820A1 (de) 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Verwendung von klk5-antagonisten zur behandlung einer krankheit
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
JP7654402B2 (ja) 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
US11293061B2 (en) * 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
CN113631910A (zh) 2019-03-29 2021-11-09 豪夫迈·罗氏有限公司 细胞表面蛋白质相互作用的调节剂及其相关方法和组合物
WO2021092079A1 (en) 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
WO2021142022A2 (en) 2020-01-06 2021-07-15 Quanta Therapeutics, Inc. Compositions and methods for identification of modulators of ras protein complexes
US11787831B2 (en) 2020-06-22 2023-10-17 Illumina Cambridge Limited Nucleosides and nucleotides with 3′ acetal blocking group
CA3200885A1 (en) 2020-11-23 2022-05-27 Genentech, Inc. Methods for modulating host cell surface interactions with sars-cov-2
AU2021386240A1 (en) 2020-11-27 2023-06-29 Genentech, Inc. Methods for modulating host cell surface interactions with human cytomegalovirus
AU2021392625A1 (en) 2020-12-01 2023-07-06 Genentech, Inc. Biological vesicles displaying cell surface proteins and methods related to same
EP4295157A1 (de) 2021-02-22 2023-12-27 Genentech, Inc. Verfahren zur modulation der interaktionen der wirtszelloberfläche mit herpesviren
EP4729942A2 (de) 2021-05-26 2026-04-22 Genentech, Inc. Verfahren zur modulation der interaktionen der oberfläche von wirtszellen mit dem humanen cytomegalovirus
CN120957747A (zh) 2023-01-20 2025-11-14 基因泰克公司 E3连接酶家族功能和相互作用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196351A (en) 1987-09-30 1993-03-23 Beckman Instruments, Inc. Bidentate conjugate and method of use thereof
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5783384A (en) 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
US5571681A (en) * 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
ES2250978T3 (es) 1994-11-01 2006-04-16 Ariad Gene Therapeutics, Inc. Nuevo metodo de identificacion y examen de moleculas con actividad bilogica.
US5958702A (en) 1995-02-06 1999-09-28 Benner; Steven Albert Receptor-assisted combinatorial chemistry
CA2249290A1 (en) 1996-03-21 1997-09-25 Rui Liang Carbohydrate-based ligand library, assay and method
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
SE9603323D0 (sv) 1996-05-14 1996-09-12 Ahlberg Catalytic method and structure
WO1998011436A1 (en) * 1996-09-13 1998-03-19 Whitehead Institute For Biomedical Research Non-specific affinity enhancement to identify combinatorial library members
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US5958703A (en) 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
US6428956B1 (en) * 1998-03-02 2002-08-06 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US7214487B2 (en) * 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
MXPA04004814A (es) * 2001-11-21 2004-08-11 Sunesis Pharmaceuticals Inc Metodos para descubrir ligandos.

Also Published As

Publication number Publication date
JP2002519668A (ja) 2002-07-02
AU4829999A (en) 2000-01-17
US20140179542A1 (en) 2014-06-26
US6811966B2 (en) 2004-11-02
US6335155B1 (en) 2002-01-01
US20020081621A1 (en) 2002-06-27
US20030104471A1 (en) 2003-06-05
IL166892A (en) 2009-09-22
DE69942451D1 (de) 2010-07-15
IL140287A (en) 2005-08-31
EP1090295A1 (de) 2001-04-11
US20070026451A1 (en) 2007-02-01
IL140287A0 (en) 2002-02-10
CA2336183A1 (en) 2000-01-06
US20020022233A1 (en) 2002-02-21
US20100022399A1 (en) 2010-01-28
EP1090295B1 (de) 2010-06-02
WO2000000823A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
ATE470150T1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
ATE337058T1 (de) Kolonne und mit dieser durchgeführtes chromatographisches verfahren
DE60029092D1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
DE60039037D1 (de) Methode zur direkten sequenzierung von nukleinsäuren
NO962991D0 (no) Zink-finger-proteinderivater og fremgangsmåter
DE69739105D1 (de) Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
ATE454469T1 (de) Für den nachweis von nukleinsäuren kompetente biologische rohderivate
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
ATE393237T1 (de) Mittel und verfahren zur in-vitro-bestimmung von camp
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
ES2191316T3 (es) Procedimiento de deteccion de un material biologico diana, fase de captura, fase de deteccion y reactivo que las contiene.
DE69924147D1 (de) Floureszenzintensitäts-test für eine protein- oder peptidbindung an nukleinsäuren
ATE357516T1 (de) Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
NO20006153L (no) Poly(ADP-ribose)polymerase gen
KR100560127B1 (ko) 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
WO2008067826A1 (en) Identification of phosphorylation sites in polypeptides by employment of uranyl photocleavage
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
Nakajima et al. A NEW STRATEGY AND TACTICS FOR PROTEIN SEQUENCING
ATE331218T1 (de) Verwendung von blauen kupferproteinen
DE59813830D1 (de) Nukleinsäuremolekülsatz für salmonella-nachweis, nukleinsäuren, kit und verwendung
KR20010074491A (ko) 고정화된 기질, 분리 겔 및 효소 활성 검출 방법
WO2005056794A3 (en) Agents for the regulation of transcription via zinc-finger proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties